Today’s FDA approval amends a previously granted accelerated approval for Balversa (erdafitinib) to treat patients with metastatic urothelial carcinoma whose tumors harbor FGFR3 or FGFR2 alterations following prior platinum-based chemotherapy.
FDA Approves Balversa for Locally Advanced, Metastatic Urothelial Carcinoma
Estimated read time
1 min read
+ There are no comments
Add yours